Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P J Mease

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Annals of the Rheumatic Diseases|March 14, 2002
Cytokine blockers in psoriatic arthritisP J Mease
Clinical and Experimental Rheumatology|June 7, 2011
The potential roles for novel biomarkers in rheumatoid arthritis assessmentP J Mease
Skin Therapy Letter|May 3, 2003
Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasisP J Mease
Annals of the Rheumatic Diseases|March 5, 2002
Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitorsP J Mease
Annals of the Rheumatic Diseases|February 15, 2005
Psoriatic arthritis treatment: biological response modifiersP J Mease, C E Antoni
Annals of the Rheumatic Diseases|February 15, 2005
Psoriatic arthritis and imagingP A Ory, D D Gladman, P J Mease
Annals of the Rheumatic Diseases|February 15, 2005
Seronegative spondyloarthropathies: to lump or split?P Nash, P J Mease, J Braun, et al.
Arthritis Care & Research|December 17, 2013
Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter studyD Gladman, R Fleischmann, G Coteur, et al.
Annals of the Rheumatic Diseases|February 15, 2005
Psoriatic arthritis assessment tools in clinical trialsP J Mease, C E Antoni, D D Gladman, et al.
Clinical Rheumatology|October 13, 2018
Correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trialJ A Walsh, A B Gottlieb, B Hoepken, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Annals of the Rheumatic Diseases|March 14, 2002
Cytokine blockers in psoriatic arthritisP J Mease
Clinical and Experimental Rheumatology|June 7, 2011
The potential roles for novel biomarkers in rheumatoid arthritis assessmentP J Mease
Skin Therapy Letter|May 3, 2003
Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasisP J Mease
Annals of the Rheumatic Diseases|March 5, 2002
Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitorsP J Mease
Annals of the Rheumatic Diseases|February 15, 2005
Psoriatic arthritis treatment: biological response modifiersP J Mease, C E Antoni
Annals of the Rheumatic Diseases|February 15, 2005
Psoriatic arthritis and imagingP A Ory, D D Gladman, P J Mease
Annals of the Rheumatic Diseases|February 15, 2005
Seronegative spondyloarthropathies: to lump or split?P Nash, P J Mease, J Braun, et al.
Arthritis Care & Research|December 17, 2013
Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter studyD Gladman, R Fleischmann, G Coteur, et al.
Annals of the Rheumatic Diseases|February 15, 2005
Psoriatic arthritis assessment tools in clinical trialsP J Mease, C E Antoni, D D Gladman, et al.
Clinical Rheumatology|October 13, 2018
Correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trialJ A Walsh, A B Gottlieb, B Hoepken, et al.
Pageof 4